GoodRx (GDRX) announced that via a collaboration with Novo Nordisk (NVO), all strengths of Ozempic and Wegovy pens are available to eligible self-paying patients for $499-per-month through GoodRx, effective immediately. This collaboration significantly lowers the price available on GoodRx for two of the most in-demand GLP-1 medications nationwide, expanding access for those who lack adequate insurance coverage. This also marks the first time Ozempic has been made available to patients at this self-pay price.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- GoodRx Earnings Call: Growth Amid Challenges
- GoodRx price target lowered to $6 from $8 at Deutsche Bank
- GoodRx Holdings: Strategic Growth and Revised Projections Support Buy Rating Despite Short-term Adjustments
- GoodRx downgraded to Outperform from Strong Buy at Raymond James
- Positive Outlook for GoodRx Holdings Amid Strategic Initiatives and Market Expansion Opportunities